drugset / Trial / NCT01160289

A Study of LY900010 in Erectile Dysfunction

NCT01160289

Phase 2 Completed 410 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.

Timeline

Start
2010-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2452473 Small molecule 1 mg Oral
Subject LY2452473 Small molecule 5 mg Oral
Subject Tadalafil Small molecule 5 mg Oral
Subject Tadalafil Small molecule 10 mg Oral

Indications